b Background: Although immunosuppression from cancer adjuvant therapy has been documented, how these suppressed immune responses recover to baseline values after completion of cancer adjuvant therapy has not been studied systematically. b Objectives: The objective of this study was to examine the probability of immune recovery after cancer adjuvant therapy and the potential impact of cancer adjuvant therapy type and cancer stage on immune recovery in patients with newly diagnosed breast cancer. b Methods: In a repeated-measures design, immune responses were measured four times in 80 patients with early-stage breast cancer: before and at 2, 6, and 12 months from the beginning of cancer adjuvant therapy. Natural killer cell activity, lymphokine-activated killer cell activity, lymphocyte proliferation, CD subsets (CD4, CD8, and CD56), and cytokines (interferon-+, interleukin [IL]-2, IL-4, IL-6, and IL-1!) were selected for their relevance to breast cancer. Immune recovery was defined by the level of immune response reaching to and above baseline levels. Data were analyzed using a multivariate generalized linear mixed-model approach.
levels continued to the 12-month time point in all parameters. The percentages of immune recovery ranged from 6% to 76% of the patients, varying among immune parameters. Overall, immune recovery was poorer for interferon-+, IL-2, IL-4, lymphocyte proliferation, and natural killer cell activity than was for CD subsets and IL-6. The type of cancer adjuvant therapy, not cancer stage, showed selective influence on immune recovery. Chemotherapy or chemotherapy and radiotherapy combination significantly delayed IL-2 recovery, whereas radiotherapy significantly delayed IL-4 recovery. b Discussion: Immune recovery after breast cancer adjuvant therapy is delayed significantly for an extended time period in numerous immune parameters. The type of cancer adjuvant therapy has selective influence on immune recovery. Future investigations are warranted to elucidate the time course of immune recovery, clinical significance of poor immune recovery, and factors influencing immune recovery to develop potential interventions. b Key Words: breast cancer & cancer treatment & immune recovery W ith the exception of skin cancer, breast cancer (BC) is the most common type of cancer and the second leading cause of death from cancer in women in the United States (American Cancer Society, 2007) . Treatments for BC include surgery, chemotherapy, radiotherapy, and hormonal and targeted therapy, often combining two or more modalities. With advances in early diagnosis and treatment, the overall survival rates are 88% at 5 years and 80% at 10 years for all stages of BC, and BC is now considered to be a chronic disease (American Cancer Society, 2007) . Accordingly, increasing attention has been paid to the long-term effects of BC diagnosis and treatment. However, most attention has been paid primarily to psychosocial outcomes but not to physiological responses.
The immune system is a major regulatory mechanism in the defense of the body. Although cancer diagnosis and adjuvant chemotherapy are known to alter immune responses significantly (Gardner, 1999; van der Most, Currie, Robinson, & Lake, 2006) , surprisingly little has been investigated about how altered immune responses recover and how the type of cancer therapy and cancer stage interact with immune recovery over time. These topics may bear even greater significance given the fact that patients with BC are found to have lower baseline immune responses than those of their healthy counterparts (Campbell, Scott, Maecker, Park, & Esserman, 2005; Caras et al., 2004; Konjevic & Spuzic, 1993) . Furthermore, poor immune recovery may increase a person's susceptibility to adverse health outcomes. There is evidence that poor recovery of lymphocyte proliferation and lymphocyte count predicted greater disease recurrence in patients with early-stage BC (Wiltschke et al., 1995) and poorer diseasefree and overall survivals in patients with metastatic BC (Nieto et al., 2004; Porrata, Ingle, Litzow, Geyer, & Markovic, 2001) .
Immune parameters of this study were selected for the relevance to BC: natural killer (NK) cell activity, lymphokine-activated killer (LAK) cell activity, CD subsets, lymphocyte proliferation, and cytokines. The NK cells participate in the resistance to and the control of malignancies (Brittenden, Heys, Ross, & Eremin, 1996; Pross & Lotzova, 1993; Whiteside & Herberman, 1995) . This NK cell activity was reduced incrementally with advances in BC stage (Konjevic & Spuzic, 1993) , and lower levels of NK cell activity were associated with a lack of cortisol diurnal variation, which then predicted a shorter survival in women with BC (Sephton, Sapolsky, Kraemer, & Spiegel, 2000) . The LAK cell activity was a sensitive predictor for emotional outcomes in patients with BC (Sachs et al., 1995) ; cytokines, interleukin (IL)-2, and interferons (IFNs) are known to enhance NK cell activity (Sinkovics & Horvath, 2005) , but IL-2 was found to be significantly lower in patients with BC than that in healthy controls before cancer treatment (Elsasser-Beile, von Kleist, & Gallati, 1991; Elsasser-Beile, von Kleist, Sauther, Gallati, & Monting, 1993) . Lower levels of IL-2 were a predictor for a shorter survival time (Lissoni, Barni, Rovelli, & Tancini, 1991) and increased risk of relapse in BC (Arduino et al., 1996) . Similarly, decreased IFN-+ production was correlated significantly with tumor burden (Elsasser-Beile et al., 1993) . In contrast, increased serum IL-6 and tumor necrosis factoralpha levels were significant predictors of shorter diseasefree and overall survival in patients with metastatic BC (Bachelot et al., 2003; Bozcuk et al., 2004) . Furthermore, lymphocyte proliferation was associated inversely with positive nodal status but was impaired in 58% of patients with BC (Head, Elliott, & McCoy, 1993) .
Although these findings clearly indicate the relevance of cellular immune responses to clinical outcomes in BC, recent studies have been focused largely on molecular or genetic markers of cancer, paying little attention to the significance of cellular immune responses. As a result, it is mostly unknown how and when immune recovery occurs after cancer treatment. In one recent study, it was indicated that impairments in enumerative and functional immune responses persisted for at least 6Y12 months after high-dose chemotherapy, although the percentage of patients demonstrating intact immune responses seemed to increase gradually with increasing time (Avigan et al., 2000) .
As a first step toward a better understanding of the role of cellular immune responses in long-term clinical outcomes of cancer, the purposes of this study were to (a) examine how immune responses recover after cancer adjuvant therapy over the first year of cancer diagnosis and treatment and (b) determine what effects the type of cancer adjuvant therapy and cancer stage have on immune recovery in patients with early-stage (IYIII) BC.
The hypotheses were as follows: (a) The probability of immune recovery to or above baseline levels would increase over time after cancer adjuvant therapy; (b) immune recovery over time would differ among the three types of cancer adjuvant therapy (chemotherapy, radiotherapy, or chemotherapy + radiotherapy); and (c) immune recovery over time would differ between two cancer stages (Stages IYII vs. greater than Stage II). Data were collected as part of a parent study, which was designed to examine the effects of an 8-week integrated intervention of cognitive behavioral modification and exercise training on psychosocial, immune, and symptom outcomes in patients with newly diagnosed BC. The effects of intervention were controlled for in the analyses of this study.
Methods

Design
The design of the parent study was a randomized clinical trial with a preintervention and postintervention (8 weeks) design with four repeated measures in women with newly diagnosed BC. Data were collected once before the intervention (baseline) and at 2, 6, and 12 months from the start of the intervention. Because intervention was coincided with the start of the cancer adjuvant therapy, the data in this study represent the baseline data before the start of the cancer adjuvant therapy and the postadjuvant therapy data at 2, 6, and 12 months from the start of the cancer adjuvant therapy.
Participants
A total of 1,127 women with BC were screened at the interdisciplinary and other breast clinics within a university health system in the southeastern region of the United States. Two hundred and thirteen patients were eligible for the study, and 100 patients enrolled in the study. Most women were not eligible for the study because they were not newly diagnosed, were already in the middle of cancer adjuvant therapy, or lived in different cities, preventing them from participation in the intervention if they were randomized into the intervention group. Among the eligible women, the two most common reasons for declining the invitation to participate were ''not having enough time to participate in the study'' and ''not interested in participating in the study.'' The parent study's sample size of 90 women (45 women in each group) was based on having a minimum of 80% power to detect differences in NK cell activity (a major immune parameter) between treatment groups and is not applicable to the aims of these secondary analyses. Because sample size was determined by the parent study for this secondary analysis, a post hoc power analysis was performed to identify the minimum effect size that could be identified given the available sample. PASS 2008 (NCSS, Kaysville, UT; Hintze, 2008) was used to perform the calculations, based on the F distribution, which is the test statistic employed for the generalized linear mixed-model analyses utilized. Keying on the time main effect, a .287 effect size would provide 80% power, given a 5% Type I error rate.
Inclusion criteria were (a) women 30 years or older with Stages IYIII BC and receiving chemotherapy and/or radiotherapy; (b) absence of a defined psychosis; (c) no uncontrolled cardiopulmonary or other serious medical conditions that would prohibit moderate-intensity exercise; (d) not participating in other structured support or exercise program; (e) ability to comprehend and follow instructions and speak and respond in English; and (f) have obtained medical clearance from a primary medical oncologist to participate in the study. Exclusion criteria were (a) pregnancy;
(b) distance preventing from weekly participation in intervention; (c) diffuse bony metastasis with high risk of pathological fractures; and (d) lack of access to a telephone. After obtaining written informed consent, patients were stratified first by cancer stage (Stages IYIIB vs. Stage III) and randomized into either intervention or waitlist control group using a computer-generated randomization table. The 8week integrated intervention was implemented at the start of adjuvant therapy, and patients were encouraged to continue their learned activities at home at the completion of the intervention. The control group received usual standard cancer care. Eighty women completed the study: 10 women from each group withdrew from the study for reasons such as chemotherapy side effects (n = 4), time commitment (n = 2), and other family and personal issues (n = 14). The protocol was approved by the institutional review board.
Data Collection Procedure
Participants were recruited by posting flyers in the clinic waiting areas; word of mouth; and invitations from clinic nurses, physicians, and research team members. The purpose and procedure of the study, what was expected from them, a need for random assignment, when and how data were to be collected, and potential risks and benefits of the study were explained fully, and questions were answered and clarified before obtaining the consent. Consent was obtained at the clinic if the participant preferred to do so. Otherwise, participants took the consent form home and mailed the consent later to the study coordinator. The study was designed in a way that most blood samples could be collected at the time of participant's routine blood work: Additional amount of blood was drawn for the study at the clinical laboratory. If this was not possible, the study coordinator who was a registered nurse traveled to the place preferred by the patient (e.g., home or office) and collected the blood samples by using routine venipuncture technique.
Immune Measurements
Blood samples for immune measurements were collected before the start of adjuvant therapy (chemotherapy, radiotherapy, or both) as baseline and at 2, 6, and 12 months after the start of adjuvant therapy. Baseline samples were collected at least 2Y3 weeks after initial surgery to control for any surgery-related impact on immune responses. All blood samples (20 ml) were collected between 08:00 AM and 12:00 AM into heparin-containing vacutainers. All assays were performed following well-established immune assay protocols.
Cell Separation Mononuclear cells (MNCs) were separated using the FicollYHypaque (1.077 sg; Sigma, St. Louis, MO) density-gradient method. MNCs were washed twice with sterile phosphate-buffered saline (PBS without Ca 2+ and Mg 2+ , pH 7.4; Gibco, Grand Island, NY), centrifuged at 450 g for 10 minutes, and were resuspended in complete RPMI 1640 (supplemented with 25 mM of HEPES, 2 mM of l-glutamine, 50 U of penicillin, and 50 2g of streptomycin/ml) at a concentration of 2 Â 10 6 cells/ml. This method has typically yielded more than 98% cell viability (Kang, Coe, & McCarthy, 1996; Kang, Coe, McCarthy, & Ershler, 1997) .
Natural Killer and LAK Cell Activity The standard chromium-51(Cr-51) release cytotoxicity assay using the K562 target cells was used (Kang et al., 1997) . Target cells were labeled with 125 2Ci Cr-51 for 1 hour at 37-C, were washed and centrifuged twice, and were resuspended at 4 Â 10 4 cells/ml. The MNCs from patients were incubated in triplicate with labeled K562 target cells and 60% heatinactivated pooled human serum in four effector-to-target cell ratiosV100:1, 50:1, 25:1, and 12.5:1. Spontaneous and maximal lysis was determined by incubating target cells with medium alone and 10% sodium dodecyl sulfate solution. After a 4-hour incubation in 5% CO 2 at 37-C, cytotoxicity was determined from supernatant using a gamma counter. Cytotoxicity was calculated as follows: NK cell activity (%) = [(sample release j spontaneous release) / (maximum j spontaneous release)] Â 100. The assay sensitivity was Q0.1%, with 2%Y6% intra-assay coefficient variation in the previous work.
For LAK cell activity, a protocol modified from studies by Brenner, Gryllis, Gornitsky, Cupples, and Wainberg (1991) and Nagao, Yabe, Xu, and Okumura (1995) was used: MNCs (1 Â 10 6 cells/ml) were incubated in complete RPMI medium containing 10% fetal calf serum and 100 U/ml recombinant IL-2 for 3 days in a humidified air of 5% CO 2 at 37-C. In the next day, LAK cells were washed twice in complete RPMI medium, cells were counted, and the same Cr-51 NK cell assay protocol was used (Brenner et al., 1991) . The assay sensitivity and variation remain the same.
Lymphocyte Proliferation The MNCs (1 Â 10 5 ) were cultured in triplicate with 60% heat-inactivated pooled human serum and phytohemagglutinin at 5 and 10 2g/ml. After a 54-hour incubation in humidified air with 5% CO 2 at 37-C, cells were pulsed with 1 2Ci of tritiated thymidine, incubated for an additional 18 hours, harvested onto glass-fiber filters (MASH harvester, Otto Hiller, Madison, WI), and were counted by a liquid scintillation counter (Packard Tricarb 300 CD, Downers Grove, IL). The results indicate the net counts per minute, controlling for unstimulated cell counts.
Cytokine Production Whole blood cell culture assay was used, which is thought to be a better method to reflect the in vivo condition than using the isolated MNC method. Blood was diluted 1:10 with the complete RPMI medium and was incubated for 4 days at 37-C with 5% CO 2 with 10 2g/ml of phytohemagglutinin and 2.5 2g/ml of lipopolysaccharide. Culture supernatant was collected and stored in aliquots at j80-C until assayed. Cytokine levels were determined by a standard two-step sandwich enzyme-linked immunosorbent assay using commercial kits. The assay sensitivity for cytokines has been reported to be 0.04Y5 pg/ml, with intra-assay and interassay percentage coefficients of variation being 4%Y9.6% for all cytokines (Biosource, San Francisco, CA; R&D Systems, Minneapolis, MN).
Cell Subsets Direct immunofluorescence method was used. Cells suspended in PBS supplemented with 0.1% sodium azide were stained using fluorescein-and phycoerythrinconjugated monoclonal antibodies against CD4, CD8, CD56, and CD3 + (pan T cells) surface markers. Cells were incubated on ice for 30 minutes, washed with PBS, and analyzed using a flow cytometer (FACScan, Becton-Dickinson, Franklin Lakes, NJ) at the FACS Shared Core Facility on campus.
Statistical Analysis
The purpose of this study was to evaluate immune recovery, relative to pretreatment levels, after BC adjuvant therapy. Of particular interest was the (a) immune recovery over time and (b) how different cancer adjuvant therapy types and cancer stage might affect recovery, after controlling for selected covariates which might influence recovery.
The response variable, immune recovery to baseline or above, was binary in nature and was evaluated at 2, 6, and 12 months after baseline. Immune recovery was coded as 1 if immune response was equal to or greater than the baseline value and as 0 if immune response was less than the baseline value. The analysis method, therefore, included (a) within-subjects (repeated-measures) effects, (b) betweensubjects effects, (c) covariates, and (d) dichotomous response variables. A generalized linear mixed-models approach, as implemented in SAS PROC GLIMMIX (SAS Institute Inc., 2005; Cary, NC), was used to analyze the data. This approach accommodates the binomial distribution of the response variables through the use of a logit link function, models dependencies produced by the repeated measures, and incorporates time-varying covariates and factors (Little, Schnabel, & Baumert, 2000; McCullagh & q Note. TNM = tumor size, nodal status, and metastasis. a One woman was originally staged as Stage I, but it was later changed to Stage 0. AC = 60 mg/m 2 of adriamycin + 600 mg/m 2 of cytoxan every 2Y3 weeks for four doses; ATC = 60 mg/m 2 of adriamycin, 145 mg/m 2 of taxol, and 600 mg/m 2 of cytoxan sequentially every 2Y3 weeks for three doses each; ACT = 50 mg/m 2 of adriamycin + 500 mg/m 2 of cytoxan together every 2Y3 weeks for four doses followed by 75 mg/m 2 of taxotere every 2Y3 weeks for four doses. McCulloch & Searle, 2001) . Multivariate models were examined for NK, LAK, and lymphocyte proliferation immune parameters to accommodate the multiple target-to-effector ratios or stimulations used for those parameters. Each model was composed of first-order type of cancer adjuvant therapy (chemotherapy, radiotherapy, or both), cancer stage (Stage II or less or greater than Stage II), hormone replacement (no or yes), menopause (premenopause, perimenopause, or postmenopause), and time (2, 6, and 12 months) effects, as well as all significant secondorder effects involving the time factor. Models were of the form ) = X" + Z+, where X" is the fixed-model component, composed of a matrix of predictor values (X) and vector of estimated regression weights ("). The Z+ term is a random term, representing the overdispersion effect. For example, the predictor (X) effects contained in the model for CD4% included time, age, cancer adjuvant cancer therapy, cancer stage, hormone replacement, menopause, and the time by cancer adjuvant cancer therapy interaction. A random multiplicative overdispersion parameter was incorporated into each model. The GLIM-MIX default estimation method (residual pseudolikelihood with a subject-specific expansion) was employed. Residuals were examined for conformity to assumptions, and model fit statistics were examined to determine the best fit covariance structure. Predictor collinearity was examined, and all variance inflation values were below 1.3, indicating no problems in terms of collinearity.
Nelder
Probability of immune recovery was estimated usinĝ Recoveryk ¼ ð1 þ e j) k Þ j1 , where) k is the model (i.e., least squares) estimate for the logit response for level k of the effect of interest (i.e., cancer treatment or time), after controlling for all other variables in the model (SAS Institute Inc., 2005) . Statistically significant interactions were followed up with simple main-effects analyses. Missing values were relatively limited to 5Y13 across all time points and all immune parameters and were not included within the analyses. Significance level was set at .05, with adjustment for multiple comparisons using the SIMULATE adjustment option implemented within PROC GLIMMIX (SAS Institute Inc., 2005).
Results
Participant Characteristics
Demographic characteristics and medical information of the participants are presented in Tables 1 and 2 33  33  28  52  52  36  33  44  56  LP5  33  25  7  43  40  25  48  38  36  LP10  33  33  29  57  30  25  33  25  43 adriamycin + 600 mg/m 2 of cytoxan every 2Y3 weeks for four doses and approximately 53% of the patients receiving either 60 mg/m 2 of adriamycin, 145 mg/m 2 of taxol, and 600 mg/m 2 of cytoxan sequentially every 2Y3 weeks for three doses each, or 50 mg/m 2 of adriamycin + 500 mg/m 2 of cytoxan every 2Y3 weeks for four doses followed by 75 mg/m 2 of taxotere every 2Y3 weeks for four doses. Type of chemotherapy regimen influence on immune recovery was examined, but there was no sufficient sample to statistically analyze three different chemotherapy regimens. On the other hand, typical radiotherapy included a total dose of 45Y65 Gy over 6 weeks, with 15Y20 Gy boost dose toward the end.
Immune Recovery Over Time
The first hypothesis was that the probability of immune recovery to or above baseline levels would increase over time after cancer adjuvant therapy. First, the percentages of the participants with immune recovery to baseline or above ranged from 17% to 62% at 2 months, 11% to 76% at 6 months, and 6% to 76% at 12 months, varying among immune parameters (Tables 3 and 4 ). Accordingly, for CD4%, IFN-+, IL-2, IL-6, LAK cell activity, and lymphocyte proliferation responses, the probability of immune recovery was significantly different across three different time points, p e .05 (Table 5 ). The IL-2 and lymphocyte proliferation responses, for example, showed further decrement in the probability of immune recovery at 12 months than that at earlier time points, whereas IL-6 showed a higher probability of recovery at 12 months. Immune recovery of CD4%, IFN-+, and LAK cell activity differed across three time points in subgroups of women based on the type of cancer adjuvant therapy received. For example, CD4% immune recovery was significantly lower at 12 months in women who received chemotherapy, whereas immune recovery of LAK cell activity was significantly higher at 12 months in women who received both chemotherapy and radiotherapy (Table 5) . Therefore, this hypothesis was supported only partially.
Immune Recovery by the Type of Cancer Adjuvant Therapy
The second hypothesis was that immune recovery over time would differ among the three types of cancer adjuvant therapy (chemotherapy, radiotherapy, or chemotherapy and radiotherapy). The type of cancer adjuvant therapy had significant effects on the probability of IL-2 and IL-4 immune recovery across all three time points (Table 6 ). The recovery of IL-2 responses was significantly poorer in women who received chemotherapy or both chemotherapy and radiotherapy than that in women who received radiotherapy only. In contrast, the recovery of IL-4 responses was significantly poorer in women who received radiotherapy than that in women who received chemotherapy or both chemotherapy and radiotherapy. For the recovery of CD4% and LAK cell activity, the type of cancer adjuvant therapy had significant q Note. Values are in percentage. Sample size may vary slightly due to missing data. IFN = interferon; IL = interleukin; NK = natural killer; LAK = lymphokineactivated killer; LP5 and LP10 = lymphocyte proliferation stimulated with phytohemagglutinin 5 and 10 2g/ml, respectively.
impact on immune recovery at only the 12-month time point: The recovery of CD4% and LAK cell activity was significantly poorer in women who received chemotherapy than that in women who received radiotherapy or both chemotherapy and radiotherapy. For other immune parameters tested in this study, the type of cancer adjuvant therapy did not show significant impact on immune recovery at any time point. Therefore, this hypothesis was supported partially.
Immune Recovery by Cancer Stage
The third hypothesis was that immune recovery over time would differ between two cancer stages (Stage IYII vs. greater than Stage 2). The probability of immune recovery to baseline or above was not significantly different by cancer stage for any immune parameters (Table 7) . In all immune parameters tested in this study, the probability of immune recovery was similar between women with BC equal to or less than Stage 2 and women with BC greater than Stage 2 at any time point. Therefore, this hypothesis was not supported.
Discussion
The findings of this study indicate that immune recovery to pretreatment levels within the first year of cancer adjuvant therapy is impaired significantly in large proportions of patients with BC. Furthermore, there is considerable variability in the extent of immune recovery among different immune parameters and patients. Not surprisingly, the type of adjuvant therapy showed significant effects on immune recovery, but those effects also varied based on immune parameters. Cancer stage, on the other hand, did not show any significant effects on immune recovery in this study perhaps because we did not have the patients with advanced-stage metastatic disease. The percentages of the patients with immune recovery to baseline or above ranged from 6% to 76% across all three time points in this study. Significant delays in immune recovery and large variability persisted at 12 months, which was at least 6Y10 months after the completion of any adjuvant therapy. It is interesting to note that enumerative parameters of CD subsets (with the exception of CD4% in chemotherapy patients) and a proinflammatory cytokine, IL-6, seem to recover faster than do other parameters that are better known to be a tumor-defense mechanism (NK cell activity) and cytokines that enhance tumor-defense mechanism (IFN-+ and IL-2). The differential speed of recovery among the different CD subsets we found is consistent with previous findings: CD8 + and CD16 + /CD56 + cells recovered faster than did CD4 + cells (Belka et al., 1999; Santin et al., 2000) , and CD4 + cell recovery remained below baseline at 4 months after a low-dose radiotherapy (Belka et al., 1999) . In patients with advanced-stage BC, high-dose chemotherapy led to an inversion of CD4/CD8 ratio and significant reductions in lymphocyte proliferation q Note. Pairs of probability with different letters (e.g., A and B, A and C, and B and C) are significantly different at p G .05. Chemo = chemotherapy; chemo + radio = both chemotherapy and radiotherapy; combined = collapsed over types of cancer adjuvant therapy as interaction with time was not statistically significant; IFN = interferon; IL = interleukin; NK = natural killer; LAK = lymphokine-activated killer; LP = lymphocyte proliferation; MV = multivariate model tested.
that persisted for 6Y12 months (Avigan et al., 2000) . Prolonged reductions in lymphocyte proliferation were also reported in patients with early-stage BC (Wiltschke et al., 1995) . Furthermore, immune recovery did not always improve with time. For example, the probability of recovering IL-2 responses to baseline or above was only approximately 19% at 12 months (Table 5) , lower than that at earlier time points. A similar decreasing trend was noted in lymphocyte proliferation responses. These findings suggest that cancer adjuvant therapy may have a delayed impact on recovery of certain immune responses far beyond the immediate period after completion of therapy. q Note. Combined = collapsed over types of cancer adjuvant therapy as interaction with time was not statistically significant; IFN = interferon; IL = interleukin; NK = natural killer; LAK = lymphokine-activated killer; LP = lymphocyte proliferation; MV = multivariate model tested.
The type of cancer adjuvant therapy had a differential influence on immune recovery in selective immune measures. Chemotherapy had significant selective immunosuppressive impact on the recovery of IL-2 responses at all times and CD4% at 12 months. In contrast, radiotherapy had significant selective immunosuppressive impact on the recovery of IL-4 responses. Immunosuppression from both chemotherapy or radiotherapy has been reported by others, including a depletion of CD4 + , CD8 + , and CD56 + subsets; impaired NK cell activity; and lymphocyte proliferation in various patients with cancer (Santin et al., 2000; Steele, 2002; Verastegui, Morales, Barrera-Franco, Poitevin, & Hadden, 2003) . The NK cell activity has been found to decrease significantly during and after chemotherapy in patients with BC, although NK cell numbers were less affected and tended to return to baseline before subsequent cycles of chemotherapy (Beitsch, Lotzova, Hortobagyi, & Pollock, 1994; Sewell et al., 1993; Solomayer et al., 2003) .
Direct comparison of three different types of cancer adjuvant therapy on immune responses has rarely been conducted. Santin et al. (2000) reported no significant differences in immune suppression between radiotherapy alone and radiotherapy combined with cisplatinum in patients with cervical cancer, but the sample size was extremely small (n = 8). Although time between completion of adjuvant therapy and blood draw for immune function measurement differed among adjuvant therapy types in this study, those differences are an unlikely explanation for differential responses because the patterns of IL-2 and IL-4 responses to adjuvant therapy types remained similar across time points. It appears that chemotherapy or combination of chemotherapy and radiotherapy suppresses T H 1-type cytokine response, whereas radiotherapy suppresses T H 2-type cytokine response.
Cancer stage had no significant effects on immune recovery in this study. Findings from prior studies have been mixed in that some found incrementally lower NK cell activity with advances in BC stage particularly among those with metastatic BC (Konjevic & Spuzic, 1993) , whereas others did not find stage-dependent reductions in immune responses (Campbell et al., 2005) . One likely reason for not observing the effect of cancer stage in this study is that patients with advanced-stage metastatic BC were not included in the study. Clinical significance of differential and impaired immune recovery is unclear now and warrants further long-term in-depth investigations. The impact of impaired immune recovery in patients with early-stage BC may be more subtle than that of clinical outcomes documented in patients with advanced-stage metastatic BC. In patients with advanced-stage BC, early immune recovery of lymphocyte count or lymphocyte proliferation responses predicted better survival and lower recurrence of disease (Nieto et al., 2004; Porrata et al., 2001) , and lower levels of IL-2 but higher levels of IL-6 were associated with significantly negative survival outcomes (Bachelot et al., 2003; Bozcuk et al., 2004) . Even in patients with earlystage BC, lower lymphocyte proliferation was correlated with greater tumor burden (tumor size and axillary lymph node involvement), and those who had not recovered their lymphocyte proliferation response to baseline values in 12 months from surgery developed a far greater rate of metastatic disease (61%) within the subsequent 2 years than did those who had recovered lymphocyte proliferation above the baseline (2%; Verastegui et al., 2003; Wiltschke et al., 1995) . Similarly, decreased intracellular IFN-+ and IL-2 expression in T cells was correlated with increased number of tumor cells in bone marrow (Campbell et al., 2005) , and lower baseline IL-2 levels were associated with a greater tumor relapse rate, 33.3% versus 4.7%, in patients with early-stage BC (Arduino et al., 1996) .
Although clinical outcomes from delayed immune recovery in patients with early-stage BC might be mostly non-life-threatening outcomes, such as infections, they can compromise patients' quality of life. Such infections were documented in 11%Y17% of patients with early-stage BC (median follow-up of 69 months; Henderson et al., 2003) and 47% of patients with metastatic BC (median follow-up of 40 weeks; Slamon et al., 2001) . Thus, research needs to be extended to determine clinical significance of delayed and poor immune recovery in patients with early-stage BC, employing large sample sizes and longer follow-up periods to gain sufficient statistical power. In addition, investigators need to simultaneously assess potential psychosocial, behavioral, disease-related, and biological factors that might contribute to variability in immune recovery. These findings may provide a basis for future interventions to facilitate a timely recovery of immune responses and perhaps improve clinical outcomes in patients with early-stage BC. q
